CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenue
Housing	$ 0	$ 41,835	$ 0	$ 136,450
Commercial rental	0	0	0	0
Tissue array products	123,419	105,107	237,230	202,936
Total revenue	123,419	146,942	237,230	339,386
Cost of Sales
Housing	0	48,923	0	133,792
Commercial rental	17,125	0	31,752	0
Tissue array products	102,176	101,493	189,324	165,952
Total cost of sales	119,301	150,416	221,076	299,744
Gross Profit	4,118	(3,474)	16,154	39,642
Operating Expenses:
Salaries and wages	41,093	45,357	81,576	389,036
Depreciation and amortization	36,721	35,376	72,993	70,733
Bad debt expense	23,226	41,943	68,830	41,943
Professional fees	10,782	8,659	57,108	32,886
Selling and distribution expenses	3,786	11,291	10,211	17,966
Other general and administrative expenses	25,407	62,386	51,762	68,342
Research and development expenses	0	2,754	0	10,157
Total Operating Expenses	141,015	207,766	342,480	631,063
Loss from Operations	(136,897)	(211,240)	(326,326)	(591,421)
Other Income (Expense)
Interest income (expense)	(1,085)	426	(598)	1,274
Other income (expense), net	(14)	428	229	27,517
Total Other Income (Expense), Net	(1,099)	854	(369)	28,791
Loss before Income Taxes	(137,996)	(210,386)	(326,695)	(562,630)
Income Tax Benefit (Expense)	0	0	0	0
Net loss	(137,996)	(210,386)	(326,695)	(562,630)
Net loss attributable to the noncontrolling interest	(28,160)	(37,036)	(53,169)	(37,140)
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES	$ (109,836)	$ (173,350)	$ (273,526)	$ (525,490)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted Average Number of Shares Outstanding
Basic and Diluted	65,756,567	64,566,567	65,756,567	64,566,567